Myeloma, Plasma-Cell clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
open to eligible people ages 18 years and up
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
at UC Davis UC Irvine UCLA
Our lead scientists for Myeloma, Plasma-Cell research studies include Gary Schiller.
Last updated: